期刊
ALZHEIMERS & DEMENTIA
卷 10, 期 6, 页码 704-712出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2013.11.009
关键词
Mild cognitive impairment; Alzheimer's disease; Cognition; MRI; PET-FDG; CSF
资金
- Litwin-Zucker Research Center of the Feinstein Institute for Medical Research (North Shore-LIJ Health System)
- National Institutes of Health [RO1 AG038734]
- ADNI (National Institutes of Health grant) [U01 AG024904]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica, Inc.
- Biogen Idec, Inc.
- Bristol-Myers Squibb Company
- Eisai, Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly
- F. Hoffmann-La Roche, Ltd.
- Genentech, Inc.
- GE Healthcare
- Innogenetics, N.V.
- IXICO, Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC
- Johnson & Johnson Pharmaceutical Research & Development, LLC
- Medpace, Inc.
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC
- NeuroRx Research
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
- Piramal Imaging
- Servier
- Synarc, Inc.
- Takeda Pharmaceutical Company
- Canadian Institutes of Health Research
Background: This study examined the predictive value of different classes of markers in the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) over an extended 4-year follow-up in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Methods: MCI patients were assessed for clinical, cognitive, magnetic resonance imaging (MRI), positron emission tomography-fluorodeoxyglucose (PET-FDG), and cerebrospinal fluid (CSF). markers at baseline and were followed on a yearly basis for 4 years to ascertain progression to AD. Logistic regression models were fitted in clusters, including demographics, APOE genotype, cognitive markers, and biomarkers (morphometric, PET-FDG, CSF, amyloid-beta, and tau). Results: The predictive model at 4 years revealed that two cognitive measures, an episodic memory measure and a Clock Drawing screening test, were the best predictors of conversion (area under the curve = 0.78). Conclusions: This model of prediction is consistent with the previous model at 2 years, thus highlighting the importance of cognitive measures in progression from MCI to AD. Cognitive markers were more robust predictors than biomarkers. (C) 2014 The Alzheimer's Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据